TwinStrand Biosciences Announces $50 Million Series B to Expand the Adoption of its Duplex Sequencing Technology in Applications Requiring the Highest Sensitivity and Accuracy
Menu
TwinStrand Biosciences Announces $50 Million Series B to Expand the Adoption of its Duplex Sequencing Technology in Applications Requiring the Highest Sensitivity and Accuracy
For Research Use Only. Not for use in diagnostic procedures.
©2024 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners. Legal Notices
Stay up to date